REFERENCES for 2004P-0349/CP-1


3. Joint Statement (concerning Thimerosal) of the American Academy of Pediatrics (AAP) and the U.S. Public Health Service (PHS), July 7, 1999; and Joint Statement Concerning Removal of Thimerosal from Vaccines of the American Academy of Family Physicians (AAFP), the American Academy of Pediatrics (AAP), the Advisory Committee on Immunization Practices (ACIP), and the U.S. Public Health Service (PHS), June 22, 2000.


29. Labeling of Visine L.R.® showing directions for use for children over 6 years of age and adults, and for children under 6 years of age to consult a doctor.

30. Labeling of FML® Ointment showing directions for use (dosage and administration).


32. Study submitted to an approved NDA: Viroptic (Trifluridine OphthalmicSolution).

33. Recommended dose in each eye: Blephamide, Ophthalmic Ointment, USP, and Cortisporin® Ophthalmic Suspension Sterile.


44. Critical Path Initiative (69 FR 21839, April 22, 2004)


47. California Environmental Protection Agency (2004). Response to the Petition of Bayer Corporation for Clarification of the Proposition 65 Listing of “Mercury and Mercury Compounds” As Chemicals Known to Cause Reproductive Toxicity, Sacramento, California.


